In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
Recent Posts
- NJ ACTS Special Populations Virtual Seminar on 9/24 at 12pm – Register Now
- NJ ACTS CREST (R25) Funded
- NJ ACTS Workforce Development Internship Fall 2024 – Deadline Today
- Rutgers Health Researchers Find Disparities in Outcomes of Hospice Discharges.
- NJIT Researchers Close in on New Technology for Objectively Measuring Pain.
Categories
- Community (1,990)
- Covid (974)
- CTO Events (1)
- News (2,536)
- Pilots (20)